Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 10 of 31 matches

Category 5 - DIAGNOSTIC IMAGING SERVICES

61523

61523 - Additional Information

Item Start Date:
01-Oct-2001
Description Updated:
22-Dec-2005
Schedule Fee Updated:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $844.50

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61524

61524 - Additional Information

Item Start Date:
01-Nov-2019
Description Updated:
01-Nov-2019
Schedule Fee Updated:
01-Nov-2019

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R)

 

 

 

Bulk bill incentive


(Anaes.)

Fee: $953.00 Benefit: 75% = $714.75 85% = $844.50

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61525

61525 - Additional Information

Item Start Date:
01-Nov-2019
Description Updated:
01-Nov-2019
Schedule Fee Updated:
01-Nov-2019

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R)

 

 

 

Bulk bill incentive


(Anaes.)

Fee: $953.00 Benefit: 75% = $714.75 85% = $844.50

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61527

61527 - Additional Information

Item Start Date:
01-Aug-2022
Description Updated:
01-Aug-2022
Schedule Fee Updated:
01-Aug-2022

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to unavailability of gallium-67 (R)

Bulk bill incentive



Fee: $752.35 Benefit: 75% = $564.30 85% = $643.85

(See para IN.4.4 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61528

61528 - Additional Information

Item Start Date:
01-Jul-2025
Description Updated:
01-Jul-2025
Schedule Fee Updated:
01-Jul-2025

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.

(R)

Bulk bill incentive


(Anaes.)

Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,191.50

Category 5 - DIAGNOSTIC IMAGING SERVICES

61529

61529 - Additional Information

Item Start Date:
01-Oct-2001
Description Updated:
22-Dec-2005
Schedule Fee Updated:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $844.50

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61530

61530 - Additional Information

Item Start Date:
01-Nov-2025
Description Updated:
01-Nov-2025
Schedule Fee Updated:
01-Nov-2025

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for:
a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, or
b) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); or
c) evaluation of response to PRRT therapy; or
d) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN.

(R)

Bulk bill incentive


(Anaes.)

Fee: $953.00 Benefit: 75% = $714.75 85% = $844.50

Category 5 - DIAGNOSTIC IMAGING SERVICES

61538

61538 - Additional Information

Item Start Date:
01-Oct-2001
Description Updated:
01-Jul-2011
Schedule Fee Updated:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)

Bulk bill incentive



Fee: $901.00 Benefit: 75% = $675.75 85% = $792.50

Category 5 - DIAGNOSTIC IMAGING SERVICES

61541

61541 - Additional Information

Item Start Date:
01-Oct-2001
Description Updated:
01-Jul-2011
Schedule Fee Updated:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)

Bulk bill incentive



Fee: $953.00 Benefit: 75% = $714.75 85% = $844.50

(See para IN.0.19 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61553

61553 - Additional Information

Item Start Date:
01-Oct-2001
Description Updated:
01-Jul-2011
Schedule Fee Updated:
01-Oct-2001

Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R)

Bulk bill incentive



Fee: $999.00 Benefit: 75% = $749.25 85% = $890.50

(See para IN.0.19 of explanatory notes to this Category)

Results 1 to 10 of 31 matches


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change